HempNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Inks MOU with BioCan Technologies

Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP), a pharmaceutical and IP development firm, this morning announced that it has entered into a Memorandum of Understanding (“MOU”) with BioCan Technologies Inc. of Calgary, Alberta to collaborate exclusively to conduct additional investigations of cannabis strains being developed by Veritas’ research arm, Cannevert Therapeutics Ltd. (“CTL”). Optimizing the genetics of the cannabis plants for scientific and clinical testing over the next two years is the company’s primary focus during the collaboration. Definitive agreements relating to the MOU are anticipated to be signed by July 31, 2018. “BioCan’s geneticists will help CTL scientists further develop proprietary strains that can produce consistent and optimal therapeutic effects in patients. We want to put in place a collaborative agreement with BioCan, which will outline this development work and related intellectual property as well as the approach to profit-sharing,” Veritas Pharma CEO, Dr. Lui Franciosi stated in the news release.

To view the full press release, visit http://cnw.fm/tH0eA

About Veritas Pharma Inc.

Veritas Pharma Inc. is an emerging pharmaceutical and IP development company, who, through its 80% owned subsidiary Cannevert Therapeutics Ltd. (“CTL”), is advancing the science behind medical cannabis. It is the Company’s aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical cannabis claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollars global markets. For more information, visit the company’s website at www.VeritasPharmaInc.com.

More from CannabisNewsBreaks

• HempNewsBreaks – Turning Point Brands Inc. (NYSE: TPB) Closes $300M Senior Secured Notes Offering 
• HempNewsBreaks – WEED Inc. (BUDZ) Announces 2024 Highlights, Plans to Expand into Consumer Packaged Goods
• HempNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Closes $3.6M Registered Direct

About HempWire

HempWire (HW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) HempNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. HW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, HW brings its clients unparalleled visibility, recognition and brand awareness. HW is where news, content and information converge.

For more information please visit https://www.hempwire.com

Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/disclaimer/

HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net